TY - JOUR
T1 - Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents
AU - Sukhija, Rishi
AU - Aronow, Wilbert S.
AU - Palaniswamy, Chandrasekar
AU - Singh, Tarunjit
AU - Sukhija, Rashmi
AU - Kalapatapu, Kumar
AU - Mohan, Diwakar
AU - Pucillo, Anthony L.
AU - Sorbera, Carmine
AU - Kakar, Priyanka
AU - Weiss, Melvin B.
AU - Lal, Purshotam
AU - Monsen, Craig E.
PY - 2010/2/1
Y1 - 2010/2/1
N2 - No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of <60 ml/min/1.73 m2, as measured by the Modification of Diet in Renal Disease (MDRD) study equation, who also underwent percutaneous coronary intervention with drug-eluting stents. Of 428 patients studied, PESs were placed in 287 patients and SESs in 141 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 47 ± 19 months of follow-up, MACE had occurred in 49 (17%) of 287 patients in the PES group (mean age 71 ± 11 years, 55% men) and in 31 (22%) of 141 patients in the SES group (mean age 71 ± 12 years, 53% men). No significant difference was found in the MACE rate between the PES and SES groups. This persisted even after controlling for stent length, lesion complexity, and other co-morbidities. Also, all-cause mortality was not significantly different between the PES and SES groups (7.1% vs 8.5%, respectively). In conclusion, during long-term follow-up of patients with moderate to severe renal insufficiency, the rates of MACE and all-cause mortality were similar in the PES and SES groups. Crown
AB - No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of <60 ml/min/1.73 m2, as measured by the Modification of Diet in Renal Disease (MDRD) study equation, who also underwent percutaneous coronary intervention with drug-eluting stents. Of 428 patients studied, PESs were placed in 287 patients and SESs in 141 patients. Stepwise Cox regression analyses were performed to identify significant independent risk factors for MACE. At 47 ± 19 months of follow-up, MACE had occurred in 49 (17%) of 287 patients in the PES group (mean age 71 ± 11 years, 55% men) and in 31 (22%) of 141 patients in the SES group (mean age 71 ± 12 years, 53% men). No significant difference was found in the MACE rate between the PES and SES groups. This persisted even after controlling for stent length, lesion complexity, and other co-morbidities. Also, all-cause mortality was not significantly different between the PES and SES groups (7.1% vs 8.5%, respectively). In conclusion, during long-term follow-up of patients with moderate to severe renal insufficiency, the rates of MACE and all-cause mortality were similar in the PES and SES groups. Crown
UR - http://www.scopus.com/inward/record.url?scp=74049125651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74049125651&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2009.09.031
DO - 10.1016/j.amjcard.2009.09.031
M3 - Article
C2 - 20102937
AN - SCOPUS:74049125651
SN - 0002-9149
VL - 105
SP - 293
EP - 296
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 3
ER -